**FLUNIXAMINE Injectable Solution**

**Indications**

FLUNIXAMINE Injectable Solution is indicated for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.

**Cattle:** FLUNIXAMINE Injectable Solution is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. FLUNIXAMINE Injectable Solution is recommended for the alleviation of inflammation and control of inflammation in endotoxemia.

**Horse:** FLUNIXAMINE Injectable Solution is indicated for the control of pyrexia associated with equine respiratory disease, endotoxemia and acute bovine mastitis. FLUNIXAMINE Injectable Solution is recommended for the alleviation of inflammation and control of inflammation in endotoxemia.

**Contraindications**

Do not use in horses intended for food. Approved only for intravenous administration in cattle. Intramuscular administration has resulted in viable residues in the edible tissues of cattle sent to slaughter.

**Precautions**

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction.

Since many NSAIDs possess the potential to induce gastrointestinal ulceration, concomitant use of FLUNIXAMINE Injectable Solution with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.

**Horse:** The effect of FLUNIXAMINE Injectable Solution on pregnancy has not been determined. Studies to determine the activity of FLUNIXAMINE Injectable Solution when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.

**Cattle:** Do not use in bulls intended for breeding, as reproductive effects of FLUNIXAMINE Injectable Solution in these classes of cattle have not been investigated. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the postestrous phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect. Do not exceed the recommended dose.

**Safety**

**Horse:**

- A 3-5 fold intramuscular dose of 1.5 mg/flb of body weight daily for 10 consecutive days was safe. No changes were observed in hematology, serum chemistry, or urinalysis values. Intravenous dosages of 0.5 mg/lb daily for 15 days; 1.5 mg/lb daily for 10 days; and 2.5 mg/lb daily for 5 days produced no changes in blood or urine parameters. No injection site irritation was observed following intravenous injection of the 0.5 mg/lb recommended dose. Some irritation was observed following a 3-fold dose administered intramuscularly.

- Cattle: No flunixin-related changes (adverse reactions) were noted in cattle administered a 1X (2.2 mg/kg; 1.0 mg/lb) dose for 9 days (three times the maximum clinical duration). Minimal toxicity manifested itself at moderately elevated doses (3X and 5X) when flunixin was administered daily for 9 days, with occasional findings of blood in the feces and/or urine. Discontinue use if hematuria or fecal blood are observed.

**Adverse Reactions**

In horses, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration, and stiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections have been reported in association with intramuscular use of flunixin meglumine. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.

**How Supplied**

FLUNIXAMINE Injectable Solution, 50 mg/mL, is available in 100 mL and 250 mL multi-dose vials. Store between 2° and 30°C (36° and 86°F). PROTECT FROM FREEZING.

**References**


Manufactured by: Bimeda-MTC Animal Health Inc.
Cambridge, ON Canada

Distributed by: Zoetis Inc.
Kalamazoo, MI 49007

Revised: March 2014